BioSpace News Archive

Athira Pharma, Inc. announced that members of Athira Pharma’s senior management team will participate in the following upcoming investor conferences.

Pardes Biosciences, Inc. today announced that it will give an oral presentation at the 35th International Conference On Antiviral Research (ICAR) 2022, to be held in Seattle and virtually from March 21-25 2022.

KemPharm, Inc. today announced that the Company has completed its analysis of the full data set from its Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of serdexmethylphenidate (SDX) delivered at doses higher than those previously studied.

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

GT Biopharma, Inc. announced today, preclinical data to be presented at the hybrid 48th European Society for Blood and Marrow Transplantation Annual Meeting.

Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022, after the markets close.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Monday, March 28, 2022

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and full year ended December 31, 2021, on Tuesday, March 29, 2022.

Fluidigm Corporation urged Fluidigm stockholders to vote “FOR” ALL proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP at the Company’s upcoming Special Meeting of Stockholders.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) for iadademstat is now approved to initiate a Phase Ib clinical trial in patients with relapsed/refractory Acute Myeloid Leukemia (AML) harboring a FMS-like tyrosine kinase mutation (FLT3mut+).